Truist Financial Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $43.00

Keros Therapeutics (NASDAQ:KROS) had its price target decreased by research analysts at Truist Financial from $100.00 to $43.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price objective would indicate a potential upside of 157.33% from the company’s current price.

A number of other equities analysts have also weighed in on KROS. Guggenheim lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, December 16th. Wedbush reiterated an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. Wells Fargo & Company raised their price objective on Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. TD Cowen lowered Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Bank of America decreased their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, Keros Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $75.00.

Keros Therapeutics Stock Performance

Shares of NASDAQ:KROS opened at $16.71 on Monday. The business’s fifty day moving average price is $54.10 and its two-hundred day moving average price is $51.40. The stock has a market cap of $676.87 million, a PE ratio of -3.21 and a beta of 1.20. Keros Therapeutics has a one year low of $15.67 and a one year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million for the quarter. During the same quarter in the prior year, the firm posted ($1.33) earnings per share. The firm’s revenue was up 4750.0% on a year-over-year basis. As a group, equities research analysts predict that Keros Therapeutics will post -5.26 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

A number of institutional investors have recently modified their holdings of KROS. Point72 Asset Management L.P. lifted its position in Keros Therapeutics by 155.9% during the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after buying an additional 577,220 shares in the last quarter. Alkeon Capital Management LLC raised its stake in shares of Keros Therapeutics by 18.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after acquiring an additional 298,694 shares during the period. Parkman Healthcare Partners LLC lifted its holdings in shares of Keros Therapeutics by 112.3% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company’s stock valued at $24,493,000 after acquiring an additional 223,155 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Keros Therapeutics by 814.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock worth $12,990,000 after purchasing an additional 199,245 shares during the period. Finally, FMR LLC boosted its position in Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after purchasing an additional 179,374 shares during the period. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.